PhoreMost extends Series B financing to $50M to advance high-value oncology and inflammation degrader programmes

16-Sep-2024 - PhoreMost Ltd. announced it has added USD $12 million to its Series B financing, bringing the total raised to over $50 million. The additional investment was led by Parkwalk Advisors, the largest growth EIS fund manager, with participation from existing investors BGF, Dr Jonathan Milner, Amadeus ...

AATec Medical starts collaboration with the German Federal Agency for Disruptive Innovation SPRIND for alpha-1 antitrypsin

SPRIND supports the development of ATL-105 for the treatment of viral respiratory diseases in various disease models

13-Feb-2024 - AATec Medical GmbH (AATec), a biotech company developing a multi-product platform based on recombinant alpha-1 antitrypsin (AAT), announces the start of its collaboration with the German Federal Agency for Disruptive Innovations (SPRIND). This project is a key step in the development of the ...

Calluna Pharma launches and announces EUR 75 million Series A financing to develop novel therapies for inflammatory and fibrotic diseases

Calluna Pharma has a pipeline of selective antibodies targeting immunological diseases

01-Feb-2024 - Oxitope Pharma (Oxitope) and Arxx Therapeutics (Arxx), companies with a shared goal of leveraging the innate immune system to discover and develop disease modulating therapies, announced their merger to form Calluna Pharma Inc. (Calluna). Calluna has raised EUR 75 million in a series A financing ...

Hope for patients with intracerebral hemorrhage

Bioxodes closes €12 million in Series A funding round

30-Nov-2023 - Bioxodes SA, a biopharmaceutical company specializing in the development of novel therapies for the prevention and treatment of thrombotic and inflammatory diseases, announces €12million ($13M) in a SeriesA funding from historic investors. This financial backing includes €8.6million ($9.3M) in ...

A promising investigational therapeutic monoclonal antibody to treat chronic hepatitis B and D infections

08-Aug-2023 - Affecting hundreds of millions of people, chronic hepatitis B is a widespread global health problem for which there is as yet no cure. In a preclinical study involving the German Center for Infection Research (DZIF), Heidelberg University Hospital, University Medical Center Hamburg-Eppendorf and ...

Development of novel proteasome inhibitors for treating cancer, inflammatory and autoimmune disorders

QLi5 Therapeutics Attracts EUR 10 Million in Series A Financing

09-Sep-2022 - Qli5 Therapeutics GmbH (QLi5), a German-Korean joint venture developing a new class of proteasome inhibitors, has closed a EUR 10 million series A financing round with an international consortium of investors including SV Investment (Korea), KHAN Technology Transfer Fund I (Germany), Atinum ...

KU Leuven spin-off AstriVax raises € 30 million to build vaccine platform

AstriVax to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection

29-Aug-2022 - Closing on € 30 million, AstriVax has raised the largest amount of seed capital in the history of KU Leuven spin-offs. The company will draw on technology developed at the KU Leuven Rega Institute to develop novel vaccines that are easy to produce, have reduced cold chain requirements, and offer ...

Study finds mushroom enzyme effective in combating hepatitis C

White mushroom enzyme has antiviral action against the hepatitis C virus and inhibits its multiplication

15-Feb-2022 - A team of CSIC researchers has co-discovered that an enzyme present in the white mushroom (Agaricus bisporus), called tyrosine, has antiviral activity against the hepatitis C virus by means of an inhibition mechanism different from that of the usual drugs. This finding, made in vitro and ...

Merck and Start-up Inbrain Neuroelectronics Collaborate to Develop the Next Generation of Bioelectronic Therapies

12-Jul-2021 - Merck, a leading science and technology company, today announced a second collaboration agreement in its Bioelectronics innovation field with Innervia Bioelectronics, a start-up and subsidiary of Inbrain Neuroelectronics S.L., Barcelona, Spain. The aim of the collaboration is to co-develop the ...

Gilead Sciences to Acquire MYR GmbH

One of the largest trade sales of a VC-financed German biotech start-up in the last 20 years - first HTGF unicorn

11-Dec-2020 - Gilead Sciences, Inc. and MYR GmbH announced that the companies have entered into a definitive agreement pursuant to which Gilead will acquire MYR for approximately €1.15 bn in cash, payable upon closing of the transaction plus a potential future milestone payment of up to €0.3 bn million (both ...